Method, device, and product for treating a body fluid of a patient with an inflammatory cytokine storm by binding an antibody to a cytokine antigen in the body fluid to form an antigen-antibody complex that is removed from the body fluid to reduce the amount of the cytokines in the body fluid

A device for treating a body fluid extracorporeally of a patient with an inflammatory cytokine storm, comprising:

• a first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber;
• a second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing a treatment into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the treatment can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid;
• and
• the device being configured to:
• remove the body fluid from a patient;
• apply a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex, wherein the antibody is selected from the group consisting of:
• an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 2 and a VL domain having the amino acid sequence of SEQ ID. No. 4 and an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 6 and a VL domain having the amino acid sequence of SEQ ID. No. 8, wherein the antigen is selected from the group consisting of:
• IL(interleukin)-1 alpha, IL-1beta, IL-2, IL-7, IL-10, IL-18, IL-36alpha, IL-36beta, IL-36gamma, IL-33, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-inducible protein 10 (IP10/CXCL10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein-1-alpha (MIP1A), and tumor necrosis factor-alpha (TNF-alpha);
• and
• remove the antibody-antigen complex from the body fluid;
• and return the body fluid to the patient.

A product for treating a body fluid extracorporeally of a patient with an inflammatory cytokine storm, comprising:

• a first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber;
• and
• a second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing a treatment into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the treatment can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex, wherein the antibody is selected from the group consisting of:
• an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 2 and a VL domain having the amino acid sequence of SEQ ID. No. 4 and an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 6 and a VL domain having the amino acid sequence of SEQ ID. No. 8, wherein the antigen is selected from the group consisting of:
• IL(interleukin)-1 alpha, IL-1beta, IL-2, IL-7, IL-10, IL-18, IL-36alpha, IL-36beta, IL-36gamma, IL-33, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-inducible protein 10 (IP10/CXCL10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein-1-alpha (MIP1A), and tumor necrosis factor-alpha (TNF-alpha).